Data on the comparative merits of drugs recommended to manage heart failure (HF) are limited. A recent case-control study compared HF patients who died within 24 months of diagnosis with those who survived to 24 months after a HF diagnosis. The researchers compared the 2 groups to see which therapies…
Read more »
Cardiovascular disease has emerged as the number one killer in both urban and rural areas of India. The Indian population is particularly susceptible to cardiovascular disease (CVD) risk factors; however, there are few large studies that have examined CVD risk factors in the Indian population. Depression is associated with an…
Read more »
Four in 10 patients hospitalized with heart failure have anemia. In such patients, several proinflammatory cytokines are independently associated with anemia, a recent study found. Investigators from The Netherlands and the United Kingdom conducted a multicenter randomized controlled clinical trial of…
Read more »
Heart failure is a common disease with high morbidity and mortality. Based on disease-specific estimates of prevalence and incidence rates of heart failure, it is estimated that the prevalence of heart failure in India due to coronary heart disease, hypertension, obesity, diabetes, and rheumatic heart disease range from 1.3 million…
Read more »
Blood levels of the carbohydrate-binding protein galectin-3 identified patients with ischemic heart failure who derived significant clinical benefit from rosuvastatin in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial. A substudy of CORONA demonstrated that patients with blood levels of galectin-3 <19.0 ng/mL at the start of the…
Read more »
mdCurrent Conference Report: American College of Cardiology’s 61st Annual Scientific Session & Expo Completing a simple 1-page checklist before discharging heart failure patients goes a long way toward reducing the number of hospital readmissions. The checklist, developed by Abhijeet Basoor, MD, a fellow in cardiovascular medicine at St. Joseph Mercy…
Read more »
indicates a Peer-Reviewed Article
India’s first successful implant of HeartMate 3™ LVAD with Full MagLev™
Patients no longer need to travel abroad for HeartMate 3™, the world’s first commercially approved fully magnetically-levitated left ventricular assist device (LVAD), proven to show high survival rates in advanced heart failure patients…
Read more »